Synaps Dx + DISCERN™
Educate patients, patient caregivers and healthcare professionals to learn more about DISCERN™, the only extremely accurate test for identifying and distinguishing Alzheimer’s Disease (AD) from other forms of dementia.
Synaps Dx and its landmark DISCERN™ test were founded to commercialize the biomarker technology developed through more than a decade of research. 325 developed a brand strategy that established DISCERN™ as its own brand to shape consumer perception and address key messaging segmented for two distinct audiences, as well as two distinct brands.
With only a corporate site and immediate deadline, 325 created an explainer, long-form landing page to maintain the imperative single call to action to learn more about the DISCERN™ test. 325 delivered targeted messaging addressing emotional and social aspects to entice audiences, HCP and patient/caregiver, to take action.
Synaps Dx was founded to commercialize the biomarker technology developed through more than a decade of research by a team of scientists at the Blanchette Rockefeller Neuroscience Institute (BRNI).
